The morning began with a breakfast N.E.X.T. Day session sponsored by Bristol-Myers Squibb. Peg Esper, DNP, ANP-BC, AOCN, discussed Opdivo (nivolumab) therapy, which is a fully human monoclonal antibody indicated for previously treated metastatic non–small-cell lung cancer. She reviewed the CheckMate 057 study, which looked at standard-of-care therapy, docetaxel, and Opdivo.